Nova Eye Medical's book value per share for the quarter that ended in Jun. 2024 was A$0.09.
During the past 12 months, Nova Eye Medical's average Book Value Per Share Growth Rate was -21.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -27.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -31.90% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -11.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Nova Eye Medical was 61.30% per year. The lowest was -44.10% per year. And the median was -0.70% per year.
Nova Eye Medical's current price is A$0.14. Its book value per share for the quarter that ended in Jun. 2024 was A$0.09. Hence, today's PB Ratio of Nova Eye Medical is 1.51.
During the past 13 years, the highest P/B Ratio of Nova Eye Medical was 3.73. The lowest was 0.43. And the median was 1.34.
Nova Eye Medical Book Value per Share Historical Data
The historical data trend for Nova Eye Medical's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Nova Eye Medical's Book Value per Share
For the Medical Devices subindustry, Nova Eye Medical's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nova Eye Medical's PB Ratio Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nova Eye Medical's PB Ratio distribution charts can be found below:
* The bar in red indicates where Nova Eye Medical's PB Ratio falls into.
Nova Eye Medical Book Value per Share Calculation
Nova Eye Medical's Book Value Per Share for the fiscal year that ended in Jun. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.
Nova Eye Medical (ASX:EYE) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Nova Eye Medical Book Value per Share Related Terms
Thank you for viewing the detailed overview of Nova Eye Medical's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Nova Eye Medical Ltd is a medical technology company that develops, manufactures, and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The company's operating segment include AlphaRET and Glaucoma Surgical Devices, it generates maximum revenue from Glaucoma Surgical Devices. Geographically, it derives a majority of its revenue from the United States of America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ASX:EYE has been successfully added to your 